These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 20375795)

  • 61. Mucinous tumor of the appendix with limited peritoneal spread: is there a role for expectant observation?
    Zih FS; Wong-Chong N; Hummel C; Petronis J; Panzarella T; Pollett A; McCart JA; Swallow CJ
    Ann Surg Oncol; 2014 Jan; 21(1):225-31. PubMed ID: 24100959
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Long-term survival in advanced ovarian carcinoma following cytoreductive surgery with standard peritonectomy procedures.
    Tentes AA; Mirelis CG; Markakidis SK; Bekiaridou KA; Bougioukas IG; Xanthoulis AI; Tsalkidou EG; Zafiropoulos GH; Nikas IH
    Int J Gynecol Cancer; 2006; 16(2):490-5. PubMed ID: 16681716
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Neoadjuvant Chemotherapy Followed by Interval Debulking Surgery and the Risk of Platinum Resistance in Epithelial Ovarian Cancer.
    da Costa AA; Valadares CV; Baiocchi G; Mantoan H; Saito A; Sanches S; Guimarães AP; Achatz MI
    Ann Surg Oncol; 2015 Dec; 22 Suppl 3():S971-8. PubMed ID: 26014155
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Gliomatosis peritonei: a particular entity with specific outcomes within the growing teratoma syndrome.
    Bentivegna E; Gonthier C; Uzan C; Genestie C; Duvillard P; Morice P; Gouy S
    Int J Gynecol Cancer; 2015 Feb; 25(2):244-9. PubMed ID: 25594144
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Population-based study of survival for women with serous cancer of the ovary, fallopian tube, peritoneum or undesignated origin - on behalf of the Swedish gynecological cancer group (SweGCG).
    Dahm-Kähler P; Borgfeldt C; Holmberg E; Staf C; Falconer H; Bjurberg M; Kjölhede P; Rosenberg P; Stålberg K; Högberg T; Åvall-Lundqvist E
    Gynecol Oncol; 2017 Jan; 144(1):167-173. PubMed ID: 27817932
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Micropapillary and cribriform patterns in ovarian serous tumors of low malignant potential: a study of 99 advanced stage cases.
    Deavers MT; Gershenson DM; Tortolero-Luna G; Malpica A; Lu KH; Silva EG
    Am J Surg Pathol; 2002 Sep; 26(9):1129-41. PubMed ID: 12218569
    [TBL] [Abstract][Full Text] [Related]  

  • 67. An open-label phase 2 study of twice-weekly bortezomib and intermittent pegylated liposomal doxorubicin in patients with ovarian cancer failing platinum-containing regimens.
    Parma G; Mancari R; Del Conte G; Scambia G; Gadducci A; Hess D; Katsaros D; Sessa C; Rinaldi A; Bertoni F; Vitali A; Catapano CV; Marsoni S; van de Velde H; Colombo N
    Int J Gynecol Cancer; 2012 Jun; 22(5):792-800. PubMed ID: 22635029
    [TBL] [Abstract][Full Text] [Related]  

  • 68. The Factors Predicting Recurrence in Patients With Serous Borderline Ovarian Tumor.
    Ureyen I; Karalok A; Tasci T; Turkmen O; Boran N; Tulunay G; Turan T
    Int J Gynecol Cancer; 2016 Jan; 26(1):66-72. PubMed ID: 26512785
    [TBL] [Abstract][Full Text] [Related]  

  • 69. [Value of tumor-reductive secondary operation (interventional laparotomy) in ovarian cancer].
    Meier W; Römisch M; Hepp H
    Geburtshilfe Frauenheilkd; 1993 Dec; 53(12):860-5. PubMed ID: 8119569
    [TBL] [Abstract][Full Text] [Related]  

  • 70. [Prognostic factors analysis in patients with ovarian malignant germ cell tumor treated with fertility-preserving surgery].
    Yang ZJ; Wei RJ; Li L
    Zhonghua Fu Chan Ke Za Zhi; 2012 Dec; 47(12):898-904. PubMed ID: 23324188
    [TBL] [Abstract][Full Text] [Related]  

  • 71. [Impact of dose delivery of postoperative first-line chemotherapy on prognosis of stage III C epithelial ovarian carcinoma].
    Zhao XD; Zhang Q; Zhang Y
    Ai Zheng; 2005 Aug; 24(8):1002-5. PubMed ID: 16086882
    [TBL] [Abstract][Full Text] [Related]  

  • 72. High Efficacy and Low Toxicity of the Modified Docetaxel and Carboplatin Protocol in Patients with Recurrent Ovarian Cancer-A Phase 2 Cohort Study.
    Bruchim I; Weeg N; Alpert Y; Sade D; Piura E; Fishman A
    Int J Gynecol Cancer; 2016 May; 26(4):640-7. PubMed ID: 27101523
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Pseudomyxoma peritonei: a review of 23 cases.
    Wertheim I; Fleischhacker D; McLachlin CM; Rice LW; Berkowitz RS; Goff BA
    Obstet Gynecol; 1994 Jul; 84(1):17-21. PubMed ID: 8008316
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Peritoneal implantations of papillary serous ovarian cystadenocarcinoma 13 days after initial laparoscopic treatment for a presumed benign ovarian cyst.
    Papoutsis D; Rodolakis A; Haidopoulos D; Sotiropoulou M; Antsaklis A
    Eur J Gynaecol Oncol; 2009; 30(1):103-5. PubMed ID: 19317271
    [TBL] [Abstract][Full Text] [Related]  

  • 75. [Evaluation of peritoneal extensions for the diagnosis and management of serous ovarian borderline tumors].
    Andrei S; Stolnicu S; Rădulescu D; Mocan S; Puşcaşu L
    Rev Med Chir Soc Med Nat Iasi; 2006; 110(3):679-86. PubMed ID: 17571566
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Ki67 expression as a predictor of chemotherapy outcome in low-grade serous ovarian cancer.
    Grabowski JP; Martinez Vila C; Richter R; Taube E; Plett H; Braicu E; Sehouli J
    Int J Gynecol Cancer; 2020 Apr; 30(4):498-503. PubMed ID: 31996397
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Ovarian psammocarcinoma with peritoneal implants.
    Cobellis L; Pezzani I; Cataldi P; Bome A; Santopietro R; Petraglia F
    Eur J Obstet Gynecol Reprod Biol; 2003 Apr; 107(2):217-9. PubMed ID: 12648875
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Timing and patterns of recurrence in epithelial ovarian cancer patients with no gross residual disease after primary debulking surgery.
    Paik ES; Lee YY; Shim M; Choi HJ; Kim TJ; Choi CH; Lee JW; Kim BG; Bae DS
    Aust N Z J Obstet Gynaecol; 2016 Dec; 56(6):639-647. PubMed ID: 27611447
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Maximal cytoreduction is related to improved disease-free survival in low-grade ovarian serous carcinoma.
    Kimyon Comert G; Turkmen O; Mesci CG; Karalok A; Sever O; Sinaci S; Boran N; Basaran D; Turan T
    Tumori; 2019 Jun; 105(3):259-264. PubMed ID: 30915911
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Carcinosarcoma of the ovary compared to ovarian high-grade serous carcinoma: impact of optimal cytoreduction and standard adjuvant treatment.
    Yalcin I; Meydanli MM; Turan AT; Taskin S; Sari ME; Gungor T; Akbayir O; Ayhan A
    Int J Clin Oncol; 2018 Apr; 23(2):329-337. PubMed ID: 29143144
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.